why choose us

First received: July 3, 2022

Clinical Trial: Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough

Study Status: Completed

Recruit Status: Completed

Condition: Post COVID-19

Study Type: Interventional


Official Title: Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough: A Randomized Controlled Pilot Study

Brief Summary: As of September 2020, the COVID-19 pandemic has affected millions of people in 196 countries and left hundreds of thousands dead. After recovery it was found that up to 32% of cases had 1 or 2 symptoms, 55% had 3 or more Post-COVID-19 symptoms, and persistent Post COVID-19 cough was recorded in 29.3% of cases in one study.A recent study identified Montelukast, among the top-scoring clinically-oriented drugs likely to inhibit SARS-CoV-2 main protease. Besides its known effect that is reported to improve cough and…

Read more